Advertisement

Picture Kentro Design Corporate and Web Design Berlin 650x65px
Organisation › Details

Targovax ASA (OSE: TRVX)

Targovax is an Oslo-area based global biotechnology company, dedicated to the design and development of immunotherapy vaccines for patients with RAS-mutated cancers. Established in 2010 by the inventors of this RAS-targeted technology and the Norwegian Radium Hospital Research Foundation in Oslo, Targovax has over 25 years of direct experience and has seen more than 250 patients treated with this promising technology. *

 

Period Start 2010-01-01 established
Products Industry TG01 (Targovax)
  Industry 2 therapeutic vaccine
Persons Person Soug, Øystein (Targovax 201809 CEO before CFO sind 201506 before Algeta + Orkla Group)
  Person 2 Furuseth, Torbjørn (Targovax 201809– CFO before Lytix Biopharma + Aker Biomarine + Trygg Pharma + McKinsey)
     
Region Region Oslo
  Country Norway
  Street 2 C Lilleakerveien
  City 0283 Oslo
  Tel +47-21-398810
    Address record changed: 2016-04-09
     
Basic data Employees B: 11 to 50 (2015-06-11)
     
    * Document for �About Section�: Targovax AS. (6/11/15). "Press Release: Targovax and Oncos Therapeutics Join Forces to Create a Nordic Leader within Immuno-oncology and Contemplate a Private Placement of NOK 125–150 Million to Fund the Combined Business [Not for US, AU, CA, JP]". Londo
     
   
Record changed: 2018-09-16

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 650x65px

More documents for Targovax ASA (OSE: TRVX)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px




» top